ClinicalTrials.gg
TerminatedNCT01151137PALLASUpdated Oct 26, 2012Results posted

Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy

A Phase 3 interventional study of Dronedarone and Placebo (for Dronedarone) in Atrial Fibrillation, sponsored by Sanofi. Terminated at 37 sites in 37 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2012-10-26.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was stopped because of safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,236
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
2nd of 26
3,236 · median 164
Started
2010
with 8 others
Phase 3
7 of 26
none open now
Registered
11th of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 2nd largest by enrollment, is one of 9 that started in 2010, is one of 7 in phase 3, and was the 11th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

Primary Objective:

  • Demonstrate the efficacy of Dronedarone in preventing major cardiovascular events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) or unplanned cardiovascular hospitalization or death from any cause in patients with permanent Atrial Fibrillation [AF] and additional risk factors

Secondary Objective:

  • Demonstrate the efficacy of Dronedarone in preventing cardiovascular death

This was an event-driven study where a common study end date [CSED] was to be determined by Steering Committee based on the number of events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death).

Read the detailed description

The study period per participant was variable depending on the enrollment in the study.

A final follow-up visit had to occur within 1 month after the CSED.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Permanent AF defined by the presence of all of the following criteria:

    • Availability of one 12-lead not more than 14 days prior to randomization showing that the patient is in AF or atrial flutter;
    • Availability of documentation (including either rhythm strips or medical report of the rhythm) showing that the patient was in AF or atrial flutter at least 6 months prior to randomization;
    • No evidence of sinus rhythm in the period between these two documentations of AF;
    • Decision of the patient and physician to allow AF to continue without further efforts to restore sinus rhythm.
  • At least one of the following risk criteria:

    • Coronary artery disease;
    • Prior stroke or [TIA];
    • Symptomatic heart failure;
    • [LVEF] less or equal to 0.40;
    • Peripheral arterial occlusive disease;
    • Aged 75 years or older with both hypertension and diabetes mellitus.

Exclusion criteria

Exclusion criteria:

  • Paroxysmal AF;
  • Persistent AF without a decision to allow AF to continue without further efforts to restore sinus rhythm;
  • Heart failure of New-York Heart Association [] class IV or recent unstable NYHA class III.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
3,236 participants (actual)

Study arms

  • Experimental
    Dronedarone

    Dronedarone 400 mg twice a day until the CSED

    Drug: Dronedarone

  • Placebo comparator
    placebo

    Placebo (for Dronedarone) twice a day until the CSED

    Drug: Placebo (for Dronedarone)

Interventions

  • Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)

    Also known as: MULTAQ, SR33589

  • DrugPlacebo (for Dronedarone)

    film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner)

06

What researchers measure

Primary outcomes

  1. Overview of the Two Co-primary Outcomes

    First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions \[MI\], or cardiovascular death. Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause. Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks \[TIA\], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause.

    Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

  2. Time to First Co-primary Outcome (Cumulative Incidence Function)

    Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.

    Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

  3. Time to Second Co-primary Outcome (Cumulative Incidence Function)

    Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.

    Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

Secondary outcomes

  1. Deaths

    Deaths were classified according to the primary cause of death.

    Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

  2. Time to Cardiovascular Death (Cumulative Incidence Function)

    Time to cardiovascular death was defined as the time from randomization to the death. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.

    Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

Other outcomes

  1. Overview of Cardiovascular Events

    Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)

  2. Overview of Adverse Events [AE]

    AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.

    Time frame: from first study drug intake up to 10 days after the last study drug intake

07

Results

Posted Oct 26, 2012
Limitations and caveats
Given that the study was prematurely discontinued after 3236 patients were randomized (30% of the initial planned number), p-values were provided for information without any adjustment for multiplicity.

Participant flow

Recruitment initiated in July 2010 was discontinued on July 6, 2011 upon recommendations of the Data Monitoring Committee due to an increased number of observed cardiovascular events in the Dronedarone group. The common study end date \[CSED\] was defined as July 15, 2011. At that time 494 sites in 37 countries had enrolled at least one patient.

Participant flow — Overall Study
MilestonePlaceboDronedarone
Started16171619
Treated16101613
Discontinued treatment171342
Completed16011591
Not completed1628
Withdrew: Death1527
Withdrew: Lost to follow-up11

Outcome measures

PrimaryOverview of the Two Co-primary Outcomes

First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions \[MI\], or cardiovascular death. Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause. Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks \[TIA\], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause.

Time frame:
From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Reported as:
Number · participants
Overview of the Two Co-primary Outcomes
participantsPlaceboDronedarone
First co-primary endpoint1943
Second co-primary endpoint67127
PrimaryTime to First Co-primary Outcome (Cumulative Incidence Function)

Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.

Time frame:
From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Reported as:
Number · proportion of participants
Time to First Co-primary Outcome (Cumulative Incidence Function)
proportion of participantsPlaceboDronedarone
Cumulative incidence at 14 days0.002 (0.000 to 0.004)0.009 (0.005 to 0.014)
Cumulative incidence at 30 days0.003 (0.000 to 0.006)0.013 (0.008 to 0.019)
Cumulative incidence at 90 days0.007 (0.003 to 0.012)0.021 (0.014 to 0.029)
Cumulative incidence at 180 days0.013 (0.006 to 0.021)0.042 (0.028 to 0.056)
Cumulative incidence at 270 days0.038 (0.012 to 0.064)0.045 (0.030 to 0.061)
Cumulative incidence at 360 days0.038 (0.012 to 0.064)0.045 (0.030 to 0.061)
Statistical analysis
  • Placebo vs Dronedarone · Log Rank · p = 0.0019 (A priori threshold for statistical significance: 0.05) · Hazard ratio (hr): 2.294 · 95% CI 1.337 to 3.936Hazard ratio (HR) of Dronedarone versus placebo for stroke, systemic arterial embolism, myocardial infarction or cardiovascular death HR and confidence interval were estimated using Cox regression model with treatment group as the only factor.
PrimaryTime to Second Co-primary Outcome (Cumulative Incidence Function)

Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.

Time frame:
From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Reported as:
Number · proportion of participants
Time to Second Co-primary Outcome (Cumulative Incidence Function)
proportion of participantsPlaceboDronedarone
Cumulative incidence at 14 days0.005 (0.002 to 0.008)0.020 (0.013 to 0.027)
Cumulative incidence at 30 days0.014 (0.008 to 0.020)0.034 (0.025 to 0.043)
Cumulative incidence at 90 days0.033 (0.023 to 0.042)0.069 (0.055 to 0.083)
Cumulative incidence at 180 days0.059 (0.043 to 0.075)0.110 (0.089 to 0.130)
Cumulative incidence at 270 days0.099 (0.062 to 0.137)0.137 (0.107 to 0.167)
Cumulative incidence at 360 days0.099 (0.062 to 0.137)0.137 (0.107 to 0.167)
Statistical analysis
  • Placebo vs Dronedarone · Log Rank · p = <0.0001 (A priori threshold for statistical significance: 0.05) · Hazard ratio (hr): 1.947 · 95% CI 1.448 to 2.617Hazard ratio (HR) of Dronedarone versus placebo for unscheduled cardiovascular hospitalization or death from any cause HR and confidence interval were estimated using Cox regression model with treatment group as the only factor.
SecondaryDeaths

Deaths were classified according to the primary cause of death.

Time frame:
From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Reported as:
Number · participants
Deaths
participantsPlaceboDronedarone
Any death1325
- Cardiovascular death1021
--- Cardiac arrhythmic death413
SecondaryTime to Cardiovascular Death (Cumulative Incidence Function)

Time to cardiovascular death was defined as the time from randomization to the death. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.

Time frame:
From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Reported as:
Number · proportion of participants
Time to Cardiovascular Death (Cumulative Incidence Function)
proportion of participantsPlaceboDronedarone
Cumulative incidence at 14 days0.001 (0.000 to 0.003)0.003 (0.000 to 0.006)
Cumulative incidence at 30 days0.003 (0.000 to 0.006)0.005 (0.002 to 0.009)
Cumulative incidence at 90 days0.004 (0.001 to 0.007)0.008 (0.003 to 0.012)
Cumulative incidence at 180 days0.004 (0.001 to 0.007)0.022 (0.012 to 0.033)
Cumulative incidence at 270 days0.027 (0.001 to 0.052)0.026 (0.013 to 0.038)
Cumulative incidence at 360 days0.027 (0.001 to 0.052)0.026 (0.013 to 0.038)
Statistical analysis
  • Placebo vs Dronedarone · Log Rank · p = 0.0460 (A priori threshold for statistical significance: 0.05) · Hazard ratio (hr): 2.115 · 95% CI 0.996 to 4.490Hazard ratio (HR) of Dronedarone versus placebo for cardiovascular death HR and confidence interval were estimated using Cox regression model with treatment group as the only factor.
Other pre-specifiedOverview of Cardiovascular Events
Time frame:
From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Reported as:
Number · participants
Overview of Cardiovascular Events
participantsPlaceboDronedarone
MI or unstable angina pectoris815
- MI23
Stroke1023
- Ischemic stroke918
Systemic arterial embolism01
Episode of heart failure55115
- Hospitalization due to heart failure2443
Unplanned hospitalization for cardiovascular cause59113
Other pre-specifiedOverview of Adverse Events [AE]

AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.

Time frame:
from first study drug intake up to 10 days after the last study drug intake
Reported as:
Number · participants
Overview of Adverse Events [AE]
participantsPlaceboDronedarone
Any AE600797
- Any serious AE77113
- Any AE leading to death04
- Any AE leading to treatment discontinuation80212
- Any AE leading to hospitalization7195

Adverse events

Collected over All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—77/1,609 (4.8%)38/1,609 (2.4%)
Dronedarone—113/1,614 (7%)100/1,614 (6.2%)
Most frequent serious events
Showing 10 of 153
Most frequent serious events
EventPlaceboDronedarone
PneumoniaInfections and infestations9/160910/1614
Renal failure acuteRenal and urinary disorders1/16098/1614
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders5/16096/1614
Hepatic enzyme increasedInvestigations1/16095/1614
HyponatraemiaMetabolism and nutrition disorders3/16090/1614
GastroenteritisInfections and infestations0/16093/1614
Gastrointestinal haemorrhageGastrointestinal disorders0/16093/1614
OsteoarthritisMusculoskeletal and connective tissue disorders2/16093/1614
Renal failureRenal and urinary disorders2/16093/1614
Urinary tract infectionInfections and infestations2/16092/1614
Most frequent other events
Most frequent other events
EventPlaceboDronedarone
DiarrhoeaGastrointestinal disorders38/1609100/1614

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboDronedaroneTotal
Mean75.0 ± 5.975.0 ± 5.975.0 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDronedaroneTotal
Female5775681145
Male104010512091
Region of Enrollment
Region of Enrollment(participants)PlaceboDronedaroneTotal
North America281266547
South America227236463
Western Europe459475934
Eastern Europe495488983
Asia5347100
Rest of the word102107209
Permanent atrial fibrillation [AF] history
Permanent atrial fibrillation [AF] history(participants)PlaceboDronedaroneTotal
6 months to 2 years490498988
> 2 years112411192243
Unknown325
CHADS2 Score
CHADS2 Score(participants)PlaceboDronedaroneTotal
< 2172191363
≥ 2144414272871
Unavailable112
New York Heart Association [NYHA] class
New York Heart Association [NYHA] class(participants)PlaceboDronedaroneTotal
No congestive heart failure [CHF]5355121047
NYHA Class I209234443
NYHA Class II7497321481
NYHA Class III124141265
08

Study locations

37 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Macquarie Park, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Sofia, Bulgaria
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Providencia Santiago, Chile
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Horsholm, Denmark
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Frankfurt, Germany
  • Sanofi-Aventis Administrative Office
    Kallithea, Greece
  • Sanofi-Aventis Administrative Office
    Hong Kong, Hong Kong
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    Col. Coyoacan, Mexico
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Auckland, New Zealand
  • Sanofi-Aventis Administrative Office
    Lysaker, Norway
  • Sanofi-Aventis Administrative Office
    Warsaw, Poland
  • Sanofi-Aventis Administrative Office
    Bucuresti, Romania
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Singapore, Singapore
  • Sanofi-Aventis Administrative Office
    Bratislava, Slovakia
  • Sanofi-Aventis Administrative Office
    Gauteng, South Africa
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Geneva, Switzerland
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administrative Office
    Kiev, Ukraine
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15;365(24):2268-76. doi: 10.1056/NEJMoa1109867. Epub 2011 Nov 14. Erratum In: N Engl J Med. 2012 Feb 16;366(7):672. PubMed 22082198 ↗
  • Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ; PALLAS investigators. Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1019-25. doi: 10.1161/CIRCEP.114.002046. Epub 2014 Nov 6. PubMed 25378467 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2010
First posted
Jun 25, 2010
Start
Jul 2010
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Oct 26, 2012
Last update
Oct 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01151137
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 25, 2010
Start date
Jul 2010
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Oct 26, 2012
Last update
Oct 26, 2012

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion